Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer

被引：0
|
作者：
Zaisheng Ye
Yi Zeng
Shenghong Wei
Yi Wang
Zhitao Lin
Shu Chen
Zhiwei Wang
Shanshan Chen
Luchuan Chen
机构：
[1] Fujian Cancer Hospital & Fujian Medical University Cancer Hospital,Department of Gastrointestinal Surgical Oncology
[2] Fujian Cancer Hospital & Fujian Medical University Cancer Hospital,Department of Fujian Provincial Key Laboratory of Tumor Biotherapy
来源：
BMC Cancer | / 21卷
关键词：
Unresectable gastric cancer; Conversion therapy; Apatinib; Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Efficacy and safety of liposome-paclitaxel/liposome-paclitaxel combined with S-1 in 17 advanced gastric cancer patients with poor performance status
    Wu, Runhong
    Shen, Zhu
    Yu, Na
    Xu, Jianhao
    Yuan, Xuya
    Ni, Liwei
    Long, Yuming
    Tao, Jialong
    Zhang, Yusong
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 1690 - 1698
  • [42] Apatinib combined with S-1 in patients with advanced pancreatic cancer causing sudden massive hemorrhage: report of two cases
    Lv, Li
    Zhang, Zhixian
    Lei, Xuefen
    Gu, Hou
    Li, Tingting
    Zhang, Wenhui
    Jiang, Lifeng
    Lin, Jie
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (06): : 6358 - 6363
  • [43] Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma
    Zhou, Liya
    Lin, Jie
    Wu, Gang
    Chen, Jiawei
    Huang, Xiaopeng
    Zhang, Shuai
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 1257 - 1261
  • [44] Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial
    Zhou, Na
    Zhang, Chuantao
    Liu, Dong
    Liu, Kewei
    Wang, Guanqun
    Zhu, Hua
    Zhang, Jianli
    Jiang, Man
    Liu, Ning
    Zhang, Xiaochun
    ONCOLOGIST, 2021, 26 (03) : E374 - E381
  • [45] Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
    Zhou, Jingxiang
    Cai, Xiaopeng
    Lu, Zhao
    Xiong, Bin
    Peng, Chunwei
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (02) : 877 - 887
  • [46] Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study
    Li, Ning
    Deng, Wenying
    Zhang, Guifang
    Du, Yali
    Guo, Yanwei
    Ma, Yijie
    Wei, Chen
    Bie, Liangyu
    Zhang, Chi
    Song, Tao
    Luo, Suxia
    Fang, Baijun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study)
    Dai, Yu-Hong
    Yu, Xiong-Jie
    Xu, Hui-Ting
    Zhuang, Liang
    Zhang, Ming-Sheng
    Zou, Yan-Mei
    Fu, Qiang
    Qiu, Hong
    Yuan, Xiang-Lin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [48] A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy
    Mimatsu K.
    Oida T.
    Kuboi Y.
    Kawasaki A.
    Kanou H.
    Kaneda H.
    Amano S.
    International Journal of Clinical Oncology, 2004, 9 (3) : 193 - 196
  • [49] Effect of theWeekly Administration of Liposome-Paclitaxel Combined with S-1 on Advanced Gastric Cancer
    Chen, Lei
    Chen, Qiang
    Zhuang, Zhixiang
    Zhang, Yusong
    Tao, Jialong
    Shen, Liqin
    Shen, Xudong
    Chen, Zhigang
    Wang, Ji
    Zhu, Minggao
    Wang, Hui
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (03) : 208 - 213
  • [50] S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study
    Lu, Yiming
    Liu, Zanchao
    Zhang, Jun
    JOURNAL OF CHEMOTHERAPY, 2014, 26 (03) : 159 - 164
12345